ARGENX Presents Positive Long-Term VYVGART Data in Myositis & Sjogren's, Reinforcing Safety Profile
Summary
ARGENX SE announced positive long-term clinical data for its drug VYVGART in myositis and Sjogren's disease, highlighting sustained patient benefits and a consistent safety profile across multiple autoimmune conditions.
Key Events
-
Sustained Benefit in Myositis
ALKIVIA+ data showed VYVGART provided sustained, clinically meaningful improvements and consistent safety in myositis patients through 52 weeks, with 37.5% maintaining major TIS improvement.
-
Maintained Response in Sjogren's Disease
RHO+ data indicated maintenance of response in Sjogren's disease patients following a switch to biweekly dosing, with low disease activity scores (median ClinESSDAI 2.0-2.5) at 72 weeks.
-
Reinforced Safety Profile
A cross-indication safety analysis confirmed VYVGART's consistent and well-tolerated safety profile across 834 treated patients and over 1,300 patient-years in autoimmune rheumatic diseases.
-
Upcoming Phase 3 Readouts
Topline results for the Phase 3 ALKIVIA study in myositis are expected in Q3 2026, and for the Phase 3 UNITY trial in Sjogren's disease in H2 2027.
Analysis
This 6-K details new clinical data for argenx's key drug, VYVGART, presented at EULAR 2026. The data from extension studies in myositis and Sjogren's disease show sustained clinical benefits and a consistent, favorable safety profile across multiple autoimmune rheumatic diseases. This reinforces the drug's broad potential and supports ongoing Phase 3 trials, which are critical for future label expansions and market growth.
At the time of this filing, ARGX was trading at $790.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.9B. The 52-week trading range was $510.06 to $934.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.